Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: Studies show that 14–68% of patients with neuroendocrine tumors (NETS) are at risk of or are malnourished. Patients’ dependent on NET type, primary or treatment are at risk of Vitamin B12, A, D E, iron deficiencies, pancreatic enzyme insufficiency (PEI) and a high HbA1c.
Conference:
Presenting Author:
Authors: Burke D, Almeamar H, O'Toole D, Barnes L, Crowley R,
Keywords: malnutrition, deficiencies, Pancreatic enzyme insufficiency, HbA1c's,
#1931 Quality of Life, Anxiety and Depression in Patients with NEN after Surgery
Introduction: Less is known about quality of life and psychiatric disorders in surgical cohort of NEN patients (pts.).
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Begum N
Authors: Begum N, Hunold H, Waldmann A, Bürk C, Keck T,
Keywords: surgery, QoL, anxiety, depression,
#1237 Risk Factors for Survival from Neuroendocrine Neoplasia with Unknown Primary Tumor Site
Introduction: Neuroendocrine neoplasia (NEN) with unknown primary site (NEN-CUP) may have a poor prognosis. We evaluated the clinical presentation, therapy, outcome, and risk factors for adverse outcomes in patients with NEN-CUP.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Begum N
Authors: Begum N, Wellner U, Thorns C, Hoffmann M, Bürk C,
Introduction: The tropomyosin receptor kinase family (TRKA, TRKB, TRKC) effects tumor cell growth in various models. Recent preclinical studies in neuroendocrine carcinoma of the lung cell lines have shown that Trk receptors might be a therapeutic target for neuroendocrine neoplasias.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Heinzle V, Reuther C, Spöttl G, Maurer J, Göke B,
Keywords: neuroendocrine tumor, trk receptor,
#739 Aspirin Inhibits Cell Viability and mTOR Signalling in Neuroendocrine Tumor Cells
Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as thymic and bronchus carcinoids. Aspirin has been reported to inhibit mTOR signalling and exhibit antitumoral activity in colorectal cancer cells. So far, no data with aspirin on NETs have been published.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Spampatti M, Vlotides G, Spöttl G, Maurer J, Göke B,
Keywords: neuroendocrine tumor, MEN-1, aspirin, mTOR,